EPI Licenses Harvard’s AQUA™ Peptide Technology
Complete the form below to unlock access to ALL audio articles.
Expression Pathology Inc. (EPI) has licensed patent rights to AQUA peptide technology from Harvard University for quantitative analysis of proteins in human and animal tissue.
AQUA technology employs labeled peptide standards to achieve absolute quantitation of target proteins in biological samples by mass spectrometry.
EPI will combine AQUA with the company’s technologies for extracting proteins from formalin fixed, paraffin embedded tissues to develop research and diagnostic applications.
"Expression Pathology’s Liquid Tissue® reagents, in combination with mass spectrometry detection, are being used by pharmaceutical companies and academic centers to discover protein biomarkers in formalinfixed tissue," said Casey Eitner, President and CEO of Expression Pathology Inc.
"By combining the AQUA and Liquid Tissue technologies, EPI will enable researchers to accurately quantitate multiple proteins in tissue samples from archival tissue collections."
"The ability to perform absolute quantitation of proteins in tissues with known therapeutic outcomes will be a powerful tool for biomarker validation."
